Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Cancer cell·2026
Same author

Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial.

The Lancet. Oncology·2026
Same author

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

Cancer cell·2026
Same author

Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

IL10R Inhibition Induces Neutrophil Tumoricidal Activity.

Cancer immunology research·2026
Same author

An ultrasmall core-shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironments.

Nature nanotechnology·2025
Same journal

The roles and diversity of alarmins in the mucosae.

Advances in immunology·2026
Same journal

Principles of resident tissue macrophages revealed by the eye.

Advances in immunology·2026
Same journal

Beyond suppression: Treg specialization in infection and tissue repair.

Advances in immunology·2026
Same journal

Ontogeny and function of microglia and nerve-associated macrophages.

Advances in immunology·2025
Same journal

Neuroimmunology beyond the CNS: Nerve-macrophage interactions in peripheral tissues.

Advances in immunology·2025
Same journal

Modulation of humoral immunity by γδ T cells: A potential adjuvant strategy for vaccination.

Advances in immunology·2025
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K

Combinatorial Cancer Immunotherapies.

Matthew D Hellmann1, Claire F Friedman1, Jedd D Wolchok1

  • 1Memorial Sloan Kettering Cancer Center, New York, NY, United States; Weill Cornell Medical College, New York, NY, United States.

Advances in Immunology
|March 1, 2016
PubMed
Summary
This summary is machine-generated.

T cell checkpoint blockade therapies are revolutionizing cancer treatment. Combining PD-1 and CTLA-4 blockade, along with other therapies, offers improved patient responses and outcomes.

Keywords:
4-1BB/CD137CTLA-4ChemotherapyCombination immunotherapyGITRIDOIL-2LAG-3OX-40Oncolytic virusPD-1PD-L1RadiationT cell checkpoint blockadeTIM-3

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Related Experiment Videos

Last Updated: Mar 25, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapeutics

Background:

  • T cell checkpoint blockade therapies are transforming cancer treatment.
  • The combination of PD-1 and CTLA-4 blockade has shown significant success in melanoma.
  • Synergistic immunotherapy combinations are crucial for improving patient outcomes.

Purpose of the Study:

  • To review the rationale and experience of T cell checkpoint blockade combinations.
  • To explore combinations with other coinhibitory/costimulatory checkpoints.
  • To investigate combinations with tumor microenvironment modulators and other anticancer modalities.

Main Methods:

  • Review of existing literature on T cell checkpoint blockade combinations.
  • Analysis of synergistic effects of combining different immunotherapies.
  • Evaluation of combinations with vaccines, chemotherapy, and radiation.

Main Results:

  • T cell checkpoint blockade, particularly PD-1 plus CTLA-4, shows promise in cancer treatment.
  • Combinatorial approaches enhance therapeutic responses and patient outcomes.
  • Targeting tumor microenvironment and other anticancer modalities alongside checkpoint blockade is beneficial.

Conclusions:

  • Combination immunotherapies, including T cell checkpoint blockade, represent a significant advancement in cancer care.
  • Further research into synergistic combinations is essential for optimizing cancer treatment strategies.
  • Integrating checkpoint blockade with diverse therapeutic modalities holds great potential for improving patient survival and quality of life.